According to the Chinese regime’s epidemic prevention policy, all parts of the mainland have regularly implemented nucleic acid testing for all employees. Many companies have made huge profits from joint business activities involved in the testing process.

Recently, a number of listed biopharmaceutical companies have successively released performance forecasts for the first half of 2022. Among them, Tianjin Jiu’an Medical Electronics Co., Ltd. (“Jiu’an Medical“) has a net profit of over 15.1 billion yuan (about 2.24 billion dollars), an increase of 27,000%.

Jiu’an Medical, still in the red in 2021, has achieved massive sales growth this year due to the sales of test kits, and its performance has soared. 

On July 14, Jiu’an Medical announced that it expects a net profit of 15.1 billion to 15.5 billion (about 2.3 billion dollars) in the first half of the year, an increase of 27,466.36%, equivalent to 54.7769 million yuan (about 8.13 million dollars) last year. 

It is worth noting that the loss in the same period last year was ~28,196.60%, equivalent to 4.7874 million yuan (about 710,000 dollars).

According to XHBY.Net, as a leading third-party medical examination company, Guangzhou Jinyu Medical Laboratory Group Co., Ltd. (referred to as “Jinyu Medical“), its half-year net profit increased by about 50% year-on-year. 

On July 15, Jinyu Medical’s 2022 semi-annual performance forecast showed that the company achieved a net profit of 1.55 billion (about 230 million dollars) to 1.68 billion yuan (about 249 million dollars), a year-on-year increase of 46.33% to 58.61%.

Wuhan Mingde Biotechnology Co., Ltd., referred to as “Mingde Bio” Antigen detection reagents have become essential anti-epidemic materials in Shanghai, Jilin, and other outbreak areas. 

On July 15, Mingde Bio disclosed the 2022 semi-annual performance forecast, and it is expected that the net profit in the first half of 2022 will be 2.4 billion (about 356 million dollars) to 2.75 billion yuan (about 400 million dollars), an increase of 314.11% to 374.50% year-on-year.

Non-net profit was 2.38 billion (about 353 million dollars) to 2.73 billion yuan (about 400 million dollars), an increase of 312.61% to 373.29% over the same period of the previous year.

On July 13, Guangzhou Daan Gene Co., Ltd. (hereinafter referred to as Daan Gene) disclosed its semi-annual performance forecast for 2022. 

It is expected to achieve a net profit of 3.3 billion to 3.7 billion yuan (about 489 million dollars to 549 dollars) attributable to shareholders of listed companies in the first half of 2022, an increase of 106.52 billion (about 1,571 billion dollars) in the same period to 131.56%.

Qi Yue (pseudonym), a resident of Jing’an District in Shanghai, said that after Shanghai lifted a three-month blockade, many places are again under lockdown, and all staff is tested for nucleic acid. 

Standing in line to take a nucleic acid test on a hot day is a mockery for ordinary people. If you don’t do it, you won’t be able to move an inch, or even be administratively detained.

If the profit chain of nucleic acid testing is not cut off, the virus will never end, and the people will never have peace.

Yang Qi (pseudonym), a resident of Changsha, Hunan, also said: [quote] “The reason why the testing agencies make a lot of money is the result of government power intervening in the economy. The epidemic is actually not as terrible as the authorities say. As long as the system does not change, the authorities can divide the society as they please, resources and social wealth.” [end quote]

Sign up to receive our latest news!

By submitting this form, I agree to the terms.